NEO1 Antibody

What is NEO1 and why is it important in research?

NEO1 (Neogenin 1) is a 160 kDa type I transmembrane protein consisting of 1461 amino acid residues in humans. As a member of the DCC (Deleted in Colorectal Cancer) protein family, NEO1 functions as a receptor for both Netrin-1 and repulsive guidance molecules (RGMs). It plays crucial roles in axon guidance, cell adhesion, and tissue patterning during development . More recently, NEO1 has gained significant attention for its involvement in inflammation regulation and tissue regeneration, making it an important target in immunology and regenerative medicine research . NEO1 is widely expressed in various tissues and cell types, including cancer cell lines, with notable expression in Ly6Chi monocytes, making it relevant for diverse research areas from neuroscience to immunology .

Which applications are most effective for NEO1 antibody detection?

Western blotting represents the most common and validated application for NEO1 antibody detection, allowing visualization of the protein's 160 kDa band . For cellular localization studies, immunohistochemistry (IHC) and immunofluorescence (IF) are effective, particularly in tissue sections where membrane localization can be visualized. Immunoprecipitation (IP) applications are valuable for protein-protein interaction studies involving NEO1 . When selecting applications, researchers should consider that different antibodies may be optimized for specific techniques - for example, antibodies targeting the N-terminal region might perform differently than those targeting the C-terminal region (AA 1411-1461) . Always validate antibody performance in your specific application before proceeding with larger experiments.

How do I select the appropriate NEO1 antibody based on species cross-reactivity?

When selecting a NEO1 antibody, carefully match the antibody's reactivity profile with your experimental model. NEO1 is highly conserved across species, with orthologs identified in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken . Available antibodies show varied cross-reactivity patterns. For example:

• Human-specific NEO1 antibodies typically recognize the human protein only

• Human/mouse antibodies can detect NEO1 in both species, making them valuable for comparative studies

• Broader reactivity antibodies may recognize NEO1 across multiple species including chicken and non-human primates

When working with less common model organisms, prioritize antibodies raised against conserved epitopes. The following considerations are recommended for cross-reactivity validation:

• Review sequence homology between your species of interest and the immunogen sequence

• Perform preliminary Western blot analyses with positive controls from validated species

• Include appropriate negative controls (NEO1 knockout samples if available)

• Consider epitope location - antibodies targeting highly conserved domains may offer better cross-reactivity

How can I optimize NEO1 antibody performance for challenging tissue samples?

Optimizing NEO1 antibody performance in challenging samples requires systematic protocol adjustments. For formalin-fixed paraffin-embedded (FFPE) tissues, which often present antigen retrieval challenges, implement the following approach:

• Heat-mediated antigen retrieval: Compare citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0) to determine optimal epitope exposure for your specific NEO1 antibody

• Extended blocking: Increase blocking time to 2 hours with 5-10% normal serum from the secondary antibody host species to reduce non-specific binding

• Signal amplification: For low NEO1 expression tissues, implement tyramide signal amplification or polymeric detection systems

• Membrane permeabilization optimization: Since NEO1 is membrane-localized, carefully titrate detergent concentration (0.1-0.3% Triton X-100) to balance membrane access without compromising epitope integrity

• Antibody concentration titration: Perform a systematic dilution series (1:100 to 1:2000) to identify the optimal signal-to-noise ratio for your specific tissue type

For frozen tissue sections, reduce fixation time and optimize permeabilization conditions, as overfixation can mask the NEO1 epitope. When working with tissues known to have high autofluorescence (brain, adipose tissue), incorporate Sudan Black B treatment (0.1-0.3%) to improve signal clarity .

What are the best methods to validate NEO1 antibody specificity?

Comprehensive validation of NEO1 antibody specificity requires multiple complementary approaches:

• Genetic controls:

  • NEO1 knockout/knockdown models provide the gold standard for specificity verification

  • Compare wild-type vs. Neo1−/− tissues to confirm antibody specificity

  • Utilize siRNA knockdown in cell lines as an accessible alternative

• Peptide competition assays:

  • Pre-incubate the antibody with immunizing peptide (targeting AA 1411-1461 for C-terminal antibodies)

  • Specific signal should be significantly reduced or eliminated

• Orthogonal technique validation:

  • Confirm protein detection by multiple methods (Western blot, IHC, mass spectrometry)

  • Verify that size, localization, and expression patterns align across techniques

  • Use multiple antibodies targeting different NEO1 epitopes to confirm consistent detection

• Isoform considerations:

  • NEO1 has four reported isoforms from alternative splicing

  • Determine which isoforms your antibody can detect based on the epitope location

  • Validate using recombinant protein standards for each isoform

What are the main challenges in NEO1 signaling pathway research and how can antibodies help address them?

NEO1 signaling research faces several challenges that can be addressed with strategic antibody applications:

• Pathway crosstalk identification:

  • NEO1 interacts with both PI3K/AKT and TGF-β pathways in monocytes

  • Use co-immunoprecipitation with NEO1 antibodies followed by mass spectrometry to identify novel interacting partners

  • Apply phospho-specific antibodies against downstream effectors (p-AKT, p-SMAD) in combination with NEO1 manipulation to map signaling networks

• Ligand-specific response differentiation:

  • NEO1 responds to multiple ligands (Netrin-1, RGMs) potentially activating different pathways

  • Utilize NEO1 antibodies in receptor blockade experiments to distinguish ligand-specific responses

  • Combine with phosphoproteomic analysis to create temporal maps of signaling events

• Cell-type specific signaling:

  • NEO1 expression is particularly high in Ly6Chi monocytes

  • Implement flow cytometry with NEO1 antibodies combined with cell surface markers to isolate specific populations for signaling studies

  • Use in situ proximity ligation assays with NEO1 antibodies to visualize protein interactions in specific cell types within complex tissues

• Temporal dynamics:

  • Capture NEO1 activation kinetics using time-course experiments with antibodies recognizing conformational changes or phosphorylation states

  • Develop phospho-NEO1 specific antibodies to directly monitor receptor activation

How does NEO1 regulate inflammation resolution mechanisms?

NEO1 functions as a critical regulator of inflammation resolution through multiple coordinated mechanisms:

• Neutrophil lifespan regulation:

  • NEO1 inhibition promotes neutrophil apoptosis, a key initiating event in resolution

  • Functional blockade of NEO1 induces expression of the anti-inflammatory decoy receptor IL-1R2

  • This process can be studied using annexin V/PI flow cytometry assays with anti-NEO1 antibody treatment

• Efferocytosis enhancement:

  • NEO1 deficiency significantly enhances phagocytosis of apoptotic neutrophils

  • This process is critical for resolution and can be quantified using fluorescently-labeled apoptotic cells and flow cytometry

  • NEO1 antibodies can be used to block function in ex vivo phagocytosis assays

• Specialized pro-resolving mediator production:

  • NEO1 deficiency increases the biosynthesis of pro-resolving lipid mediators including:

    • Lipoxin A4

    • Maresin-1

    • Protectin DX

  • These mediators can be measured by liquid chromatography-tandem mass spectrometry in experimental models comparing wild-type and Neo1−/− conditions

• Monocyte phenotype modulation:

  • NEO1 expression is limited to inflammatory Ly6Chi monocytes

  • NEO1 deficiency shifts monocyte polarization toward anti-inflammatory Ly6Clo phenotype

  • This transition can be tracked using flow cytometry with appropriate surface markers alongside NEO1 antibodies

What experimental approaches best demonstrate NEO1's role in tissue regeneration?

To effectively investigate NEO1's role in tissue regeneration, researchers should consider these experimental approaches:

• Wound healing models:

  • Create standardized wounds in WT and Neo1−/− mice

  • Track closure rates over time with digital imaging

  • Implement tissue-specific NEO1 knockout models using Cre-lox systems to distinguish between effects in different cell populations

  • Use NEO1 antibodies in immunohistochemistry to correlate expression patterns with healing phases

• Lineage tracing studies:

  • Utilize Neo1-CreER mouse models crossed with fluorescent reporter lines

  • Induce labeling at different timepoints during the regeneration process

  • Track the fate of NEO1-expressing cells during tissue repair

  • Combine with single-cell RNA-seq to identify transcriptional signatures of NEO1+ cells

• Functional blockade experiments:

  • Apply NEO1-blocking antibodies to wounds at different timepoints

  • Compare outcomes with isotype controls

  • Assess both macroscopic (closure rate) and microscopic (histological) parameters

  • Evaluate inflammatory marker expression via multiplex cytokine assays

• Cellular mechanism investigations:

  • Utilize ex vivo organoid models from WT and Neo1−/− tissues

  • Assess regenerative capacity after controlled damage

  • Implement live imaging with fluorescently-tagged NEO1 to track cellular dynamics during repair

  • Combine with phosphoproteomic analysis to map signaling networks activated during regeneration

What methods can accurately quantify NEO1-dependent changes in inflammation models?

Precise quantification of NEO1-dependent inflammatory changes requires multidimensional approaches:

• Temporal leukocyte migration assessment:

  • In peritonitis models, collect peritoneal lavage at defined timepoints (0, 4, 12, 24, 48h)

  • Quantify neutrophil and monocyte subsets by flow cytometry

  • Calculate resolution indices:

    • Ψmax (maximum neutrophil number)

    • Tmax (time point of maximum neutrophil infiltration)

    • T50 (time to 50% neutrophil reduction)

    • Resolution interval (Ri = T50 - Tmax)

• Apoptosis quantification:

  • Measure neutrophil apoptosis by flow cytometry (Annexin V/PI staining)

  • Assess caspase-3 activation by immunoblotting or activity assays

  • Implement TUNEL staining in tissue sections

  • Compare results between WT and Neo1−/− conditions or antibody-treated samples

• Efferocytosis measurement:

  • Label apoptotic neutrophils with pHrodo or CFSE

  • Co-culture with macrophages under different NEO1 manipulation conditions

  • Quantify phagocytosis by flow cytometry or confocal microscopy

  • Calculate phagocytic index (number of ingested cells per phagocyte)

• Lipidomic analysis:

  • Extract lipids from inflammatory exudates

  • Perform targeted LC-MS/MS analysis of specialized pro-resolving mediators

  • Compare profiles between WT and Neo1−/− conditions

  • Correlate with resolution indices and clinical outcomes

Note: This table represents consolidated data based on published findings with Neo1-deficient models .

What are the key technical considerations for successful Western blot detection of NEO1?

Successful Western blot detection of NEO1 requires attention to several technical parameters:

• Sample preparation optimization:

  • NEO1 is a 160 kDa membrane protein requiring careful extraction

  • Use RIPA buffer supplemented with 1% NP-40 and 0.5% sodium deoxycholate

  • Include protease inhibitor cocktail and phosphatase inhibitors

  • Avoid excessive heating (>70°C) which can cause aggregation of membrane proteins

  • Sonicate briefly (3-5 pulses) to improve membrane protein solubilization

• Gel selection and transfer parameters:

  • Use 6-8% polyacrylamide gels or 4-12% gradient gels to optimize separation

  • Transfer large proteins at lower voltage (30V) for extended periods (overnight)

  • Add 0.1% SDS to transfer buffer to aid large protein migration

  • Use PVDF membrane (0.45 μm pore size) rather than nitrocellulose for better retention

• Antibody optimization:

  • Typical starting dilutions range from 1:500 to 1:2000

  • Extended primary antibody incubation (overnight at 4°C) improves signal

  • Test multiple antibodies targeting different epitopes (N-terminal vs. C-terminal)

  • For glycosylated NEO1 detection, consider enzymatic deglycosylation before loading

• Signal detection considerations:

  • Use enhanced chemiluminescence with extended exposure times (1-5 minutes)

  • For weak signals, consider fluorescent secondary antibodies with digital imaging systems

  • Include positive controls (cell lines with known NEO1 expression)

  • Verify size with appropriate molecular weight markers spanning 100-250 kDa range

How should NEO1 antibodies be used in flow cytometry for immune cell analysis?

Effective flow cytometric analysis of NEO1 requires careful protocol optimization:

• Cell preparation protocol:

  • Use gentle dissociation methods to preserve membrane integrity

  • For tissue samples, enzymatic dissociation should be optimized (collagenase D at 1-2 mg/ml, 30 minutes at 37°C)

  • Maintain cells at 4°C during processing to minimize receptor internalization

  • Fix with 2% paraformaldehyde only if absolutely necessary, as it may affect epitope recognition

• Staining optimization:

  • Test both extracellular and intracellular staining protocols

  • For extracellular domains, stain live cells before fixation

  • For intracellular epitopes, use 0.1% saponin or 0.3% Triton X-100 for permeabilization

  • Implement Fc receptor blocking (10-15 minute pre-incubation)

  • Titrate antibody concentration starting at 1-5 μg per million cells

• Panel design for monocyte/macrophage analysis:

  • Include markers to identify subpopulations:

    • Ly6C (high/low monocyte subsets)

    • CD11b (myeloid lineage)

    • F4/80 (macrophages)

    • CCR2 (inflammatory monocytes)

  • Incorporate functional markers:

    • Annexin V (apoptosis)

    • Phagocytosis indicators

  • Use appropriate compensation controls for each fluorophore

• Analysis strategies:

  • Gate sequentially: Size → Singlets → Live cells → Myeloid cells → Monocyte subsets

  • Analyze NEO1 expression as median fluorescence intensity (MFI)

  • Use FMO (fluorescence minus one) controls to set positive/negative boundaries

  • Compare expression between Ly6Chi and Ly6Clo populations

  • Correlate with activation/polarization markers

How can NEO1 expression be reliably quantified in clinical samples?

Reliable quantification of NEO1 in clinical samples requires standardized approaches:

• Immunohistochemistry quantification:

  • Use automated staining platforms for consistency

  • Implement digital pathology analysis with validated algorithms

  • Score intensity (0-3+) and percentage of positive cells

  • Calculate H-score (0-300) = Σ (intensity × percentage)

  • Include internal control tissues on each slide

  • Assess membrane vs. cytoplasmic localization separately

• ELISA/immunoassay development:

  • NEO1 can be detected in plasma/serum samples

  • Establish assay-specific reference ranges from healthy controls

  • Implement spike-recovery experiments to validate accuracy

  • Test for interference from common medications

  • Evaluate pre-analytical variables (collection tubes, processing time)

• Transcript quantification:

  • Design qPCR primers spanning exon-exon junctions

  • Target regions common to all known isoforms

  • Normalize to validated reference genes (GAPDH, ACTB, B2M)

  • Consider digital droplet PCR for absolute quantification

  • Implement RNA integrity assessment before analysis

• Clinical correlation analysis:

  • NEO1 levels correlate with clinical parameters in critical illness:

    • Abdominal compartment syndrome

    • Pediatric Risk of Mortality III (PRISM-III) score

    • ICU length of stay

    • Mortality

  • Implement multivariate analysis to identify independent associations

  • Consider receiver operating characteristic (ROC) analysis to determine optimal cutoff values

Note: This table represents consolidated data based on published clinical findings with Neo1 measurements in pediatric ICU patients .

How might NEO1 targeting be developed into therapeutic applications?

NEO1 targeting strategies show promising therapeutic potential through several mechanisms:

• Antibody-based therapeutic approaches:

  • Develop neutralizing antibodies against functional domains

  • Optimize affinity and specificity through antibody engineering

  • Test Fab fragments versus full IgG for tissue penetration differences

  • Evaluate combinatorial approaches with existing anti-inflammatory agents

  • Design protocols for:

    • Acute inflammatory conditions

    • Chronic inflammatory diseases

    • Tissue injury models

• Small molecule inhibitor development:

  • Target the NEO1-Netrin-1 or NEO1-RGM interaction interfaces

  • Screen compound libraries against crystallographic structures

  • Develop assays measuring:

    • Binding inhibition

    • Receptor dimerization

    • Downstream signaling (PI3K/AKT pathway)

    • Functional outcomes in monocyte polarization models

• Cell-based therapy approaches:

  • Generate NEO1-modified monocytes/macrophages

  • Use CRISPR/Cas9 to create NEO1-deficient therapeutic cells

  • Evaluate adoptive transfer protocols in inflammatory disease models

  • Combine with proresolving mediator treatment

• Biomarker development:

  • Validate NEO1 as a prognostic indicator in critical illness

  • Develop point-of-care testing for rapid assessment

  • Integrate into multiparameter disease severity scores

  • Create algorithms for patient stratification based on NEO1 levels

What experimental strategies can resolve contradictory findings in NEO1 research?

Addressing contradictory findings in NEO1 research requires systematic approaches:

• Context-dependent function analysis:

  • NEO1 may exhibit different functions depending on:

    • Cell type (neurons vs. immune cells)

    • Developmental stage

    • Inflammatory state

    • Ligand availability

  • Design experiments testing identical manipulations across multiple contexts

  • Use conditional knockout models with tissue-specific or inducible Cre expression

  • Implement temporal control with drug-inducible systems

• Isoform-specific investigation:

  • The four NEO1 isoforms may have distinct functions

  • Develop isoform-specific antibodies and detection methods

  • Use isoform-selective knockdown approaches

  • Characterize expression patterns across tissues and conditions

  • Perform complementation studies with individual isoforms

• Species difference reconciliation:

  • Compare NEO1 functions across species (human, mouse, etc.)

  • Perform cross-species sequence and domain analyses

  • Develop humanized mouse models for translational studies

  • Use primary cells from multiple species in parallel experiments

• Pathway integration strategies:

  • Map NEO1 signaling comprehensively using phosphoproteomics

  • Identify context-specific binding partners through BioID or proximity labeling

  • Develop mathematical models of NEO1 signaling networks

  • Test predictions systematically using combinatorial pathway manipulation

How can single-cell technologies advance our understanding of NEO1 biology?

Single-cell technologies offer unprecedented opportunities to elucidate NEO1 biology:

• Single-cell transcriptomics applications:

  • Map NEO1 expression across cell types in complex tissues

  • Identify co-expression patterns with ligands and downstream effectors

  • Characterize transcriptional responses to NEO1 manipulation

  • Perform trajectory analysis to understand temporal dynamics during:

    • Inflammation progression and resolution

    • Tissue regeneration

    • Developmental processes

• Single-cell proteomics approaches:

  • Develop CyTOF panels including NEO1 and signaling markers

  • Implement cellular indexing of transcriptomes and epitopes (CITE-seq)

  • Correlate NEO1 protein levels with cell surface phenotypes

  • Track phosphorylation cascades at single-cell resolution

• Spatial transcriptomics integration:

  • Map NEO1 expression in tissue context

  • Identify ligand-receptor interactions in situ

  • Characterize NEO1+ cell niches and microenvironments

  • Correlate with histopathological features in disease tissues

• Multi-omics integration strategies:

  • Combine single-cell RNA-seq with ATAC-seq for regulatory insights

  • Correlate transcriptional and epigenetic features with NEO1 expression

  • Develop computational frameworks to integrate multiple data types

  • Build predictive models of NEO1 regulation and function across cell states